Study of Butylphthalide to Improve Brain Function After Cardiac Arrest in Adults Aged 18 to 80 Randomized, Double-Blind, Placebo-Controlled Trial

What this Trial Is About

Researchers are studying the potential benefits of Butylphthalide NBP, a neuroprotective drug, in improving neurological outcomes for patients who have experienced cardiac arrest and have regained spontaneous circulation ROSC. The trial aims to evaluate the safety and effectiveness of NBP in reducing brain injury caused by lack of oxygen and blood flow after cardiac arrest. This is a randomized, double-blind, placebo-controlled study conducted at a single center. Participants will be randomly assigned to receive either an intravenous infusion of Butylphthalide combined with sodium chloride or a saline placebo. Both treatments are given twice daily for 14 days, starting within 6 hours after ROSC. All patients will also receive standard care according to international guidelines during the study. The study groups are compared to assess NBPs neuroprotective effects. During the study, participants will be monitored closely for neurological function using the Cerebral Performance Category CPC score at 90 days after treatment begins. Safety will be tracked by recording any severe adverse events during the 14-day treatment period. The trial involves regular evaluations to ensure participant safety and to measure the drugs impact on brain recovery following cardiac arrest.

Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial)